Diabetes
From the Journals
New genetic variant linked to maturity-onset diabetes of the young
The reported variant in Greenlandic Inuit individuals has the largest population impact of any previously reported variant within a MODY gene.
Feature
Will ICER review aid bid for Medicare to pay for obesity drugs?
An influential group urges both a reduction in costs of certain obesity medicines and expanded insurance coverage of them. The recommendations are...
From the Journals
Night lights in the city link to increased risk of diabetes
Impairment in glucose homeostasis and indicators of diabetes were significantly correlated with higher amounts of exposure to outdoor artificial...
Feature
Medical school culinary medicine programs grow despite limited funding
As part of Dr. Marvasti’s program, students learn cooking fundamentals through chef demonstrations and hands-on practice – to teach students how...
Commentary
New recommendations for hyperglycemia management
These are incredibly important guidelines that provide a clear algorithm for a personalized approach to diabetes management.
Feature
Patients complain some obesity care startups offer pills, and not much else
A wave of startups offer access to a new category of weight-loss drugs coupled with intensive behavioral coaching online. But already concerns are...
From the Journals
‘Key cause’ of type 2 diabetes identified
“This suggests a potential way in which the decline in beta-cell function in T2D might be slowed or prevented.”
Conference Coverage
Statins boost glycemia slightly, but CVD benefits prevail
Meta-analysis of 23 trials confirmed statins raise glycemia and can trigger diabetes, but the effect pales compared with their CVD prevention.
From the Journals
Has the time come for glucose monitors for people without diabetes?
The increasing popularity of continuous glucose monitoring devices in prediabetes and for ‘wellness’ prompts discussion about appropriate use and...
Conference Coverage
New dual-agonist weight-loss injection impressive, but early days
The “bottom line” is that this potential new antiobesity/diabetes drug is “very promising, but [it is] still a little early to say where it...
Conference Coverage
Tirzepatide lowers weight across all groups with obesity
The antiobesity medication semaglutide “took things up one big notch, and now tirzepatide is up a little notch above that,” one expert said.